Impulsive and compulsive behaviors in Parkinson's disease
Antiparkinson therapy can be the primary cause of a range of nonmotor symptoms that include a set of complex disinhibitory psychomotor pathologies and are linked by their repetitive, reward or incentive‐based natures. These behaviors relate to aberrant or excessive dopamine receptor stimulation and...
Saved in:
Published in | Movement disorders Vol. 24; no. 11; pp. 1561 - 1570 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15.08.2009
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Antiparkinson therapy can be the primary cause of a range of nonmotor symptoms that include a set of complex disinhibitory psychomotor pathologies and are linked by their repetitive, reward or incentive‐based natures. These behaviors relate to aberrant or excessive dopamine receptor stimulation and encompass impulse control disorders (ICDs), punding, and the dopamine dysregulation syndrome (DDS). Common ICDs include pathological gambling, hypersexuality, compulsive eating, and compulsive buying. This review focuses on the phenomenology, epidemiology, and methods to identify and rate these disorders. The management of dopaminergic drug‐related compulsive behaviors is discussed in the light of the current understanding of the neurobiological substrate of these disorders. © 2009 Movement Disorder Society |
---|---|
Bibliography: | Potential conflict of interest: Dr Evans has received honoraria from Boehringer Ingelheim, and Novartis. Dr Strafella has no relevant financial disclosures. Dr. Weintraub has served as a consultant, is on an advisory board, and has received grant support from Boehringer Ingelheim. Dr. Stacy serves on the steering committee for the Boehringer Ingelheim sponsored DOMINION trial, and the study principal investigator for the Novartis sponsored nonmotor symptoms of wearing off in PD. He has received honoraria from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and TEVA. ark:/67375/WNG-89TWBDWS-4 ArticleID:MDS22505 istex:18A9B5CBCB3B8D28AB7EDCDA16D7530FDEDE2F60 This article is part of the journal's online CME program. The CME activity including form, can be found online at http://www.movementdisorders.org/education/journalcme/ http://www.movementdisorders.org/education/journalcme/ This article is part of the journal's online CME program. The CME activity including form, can be found online at ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.22505 |